Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Cost-Effectiveness Analysis of Posaconazole versus Liposomal Amphotericin B in the Treatment of Mucormycosis patients in Iran

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: TAHERI, Saeed (Shahid Beheshti University of Medical Science, Dept. of pharmacoeconomics and Pharma Management, Tehran, Iran, Islamic Republic Of)
  • Co-author(s): Saeed Taheri: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
    Leila Zarei: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
    Alireza Ghiamat: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
    Gholamhossein Mehralian: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
  • Abstract:

    Backgrounds

    Mucormycosis is an invasive fungal infection with high mortality specially in decompensated diabetics and immunosuppressed patients. The Mucorales are inherently resistant to most widely used antifungal agents. Liposomal Amphotericin B (AmB) is an appropriate option for empirical therapy, whereas Posaconazole (PCZ), a new..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses